Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial

Nicotine and Tobacco Research

Volumn 9, Issue 11, 2007, Pages 1237-1241

  Ray, Riju ^a   Jepson, Christopher ^b   Wileyto, E Paul ^a   Dahl, John P ^a   Patterson, Freda ^b   Rukstalis, Margaret ^b   Pinto, Angela ^b   Berrettini, Wade ^a   Lerman, Caryn ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1; MU OPIATE RECEPTOR; NICOTINE; NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; PATIENT COUNSELING; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADULT; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, OPIOID, MU; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 35248821416     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200701648367     Document Type: Article

References (18)

1. Berrendero, F., Kieffer, B. L. and Maldonado, R. (2002) Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. The Journal of Neuroscience, 22, pp. 10935-10940.
2. Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. and Caron, M. G. (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature, 408, pp. 720-723.
3. Bohn, L. M., Gainetdinov, R. R., Sotnikova, T. D., Medvedev, I. O., Lefkowitz, R. J., Dykstra, L. A. and Caron, M. G. (2003) Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. The Journal of Neuroscience, 23, pp. 10265-10273.
4. Crowley, J. J., Oslin, D. W., Patkar, A. A., Gottheil, E., DeMaria Jr., P. A., O'Brien, C. P., Berrettini, W. H. and Grice, D. E. (2003) A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatric Genetics, 13, pp. 169-173.
5. Enoch, M. A. (2003) Pharmacogenomics of alcohol response and addiction. The American Journal of Pharmacogenomics, 3, pp. 217-232.
6. Gainetdinov, R. R., Premont, R. T., Bohn, L. M., Lefkowitz, R. J. and Caron, M. G. (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annual Review of Neuroscience, 27, pp. 107-144.
7. Guang, W., Wang, H., Su, T., Weinstein, I. B. and Wang, J. B. (2004) Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Molecular Pharmacology, 66, pp. 1285-1292.
8. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C. and Fagerström, K. O. (1991) The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, pp. 1119-1127.
9. Jorde, L. B. (2000) Linkage disequilibrium and the search for complex disease genes. Genome Research, 10, pp. 1435-1444.
10. Kovoor, A., Nappey, V., Kieffer, B. L. and Chavkin, C. (1997) Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in Xenopus oocytes. The Journal of Biological Chemistry, 272, pp. 27605-27611.
11. Lerman, C., Kaufmann, V., Rukstalis, M., Patterson, F., Perkins, K., Audrain-McGovern, J. and Benowitz, N. (2004) Individualizing nicotine replacement therapy for the treatment of tobacco dependence: A randomized trial. Annals of Internal Medicine, 140, pp. 426-433.
12. Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S., Shields, P. G., Kaufmann, V., Redden, D., Benowitz, N. and Berrettini, W. H. (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal, 4, pp. 184-192.
13. Munafò, M. R., Shields, A. E., Berrettini, W. H., Patterson, F. and Lerman, C. (2005) Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics, 6, pp. 211-223.
14. Qiu, Y., Law, P. Y. and Loh, H. H. (2003) Mu-opioid receptor desensitization: Role of receptor phosphorylation, internalization, and representation. Journal of Biological Chemistry, 278, pp. 36733-36739.
15. Schaid, D. J., Rowland, C. M., Tines, D. E., Jacobson, R. M. and Poland, G. A. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. American Journal of Human Genetics, 70, pp. 425-434.
16. Sinwell, J. P. S. (2005) Haplo Stats version 1.2.1, Mayo Clinic, Rochester, MN
17. SRNT Subcommittee on Biochemical Verification (2002) Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4, pp. 149-159.
18. Walters, C. L., Cleck, J. N., Kuo, Y. C. and Blendy, J. A. (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron, 46, pp. 933-943.